Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
5,964 total articles
Science Applications International (SAIC) trades at a low-teens P/E and generates strong free cash flow, yet recent procurement delays and weaker award outcomes mean revenue growth is uncertain. We favor a cautious long: enter at the current price, cap position size, use a clear stop, and target a re-rating toward prior multiple and contract recove…
LexinFintech (LX) looks cheap on headline metrics and is showing improving profitability and product momentum. Management’s $50M repurchase and a planned $10M CEO purchase, plus consecutive quarterly profit improvements and AI-driven product wins, create a constructive setup. This is a tactical long with a clear entry, stop and target, but the trad…
Diamondback (FANG) looks expensive for the profile: market cap roughly $54B, negative free cash flow, thin cash buffer, and a stretched P/E near 200 despite modest returns on capital. The Iran-related oil rally has pumped the sector, but that same rally is encouraging rotation into integrated majors and fee-based midstream names while exposing sing…
BYD's combination of scale across passenger and commercial EVs, a $113.3B market cap, improving export guidance and an attractive risk/reward near $11.58 make it a pragmatic long. This trade plan sets an entry at $11.58, a $16.50 target and a $10.50 stop for a long-term (180 trading days) position while explaining catalysts, valuation logic and maj…
Nvidia's fundamentals and cash generation are massive, earnings power is resilient, and recent industry signals (memory shortages, surging HBM demand, and Jensen Huang's capital commitments) point to upside that the consensus hasn't fully baked in. This trade idea lays out an actionable long with entry, stops, targets, catalysts and risks for a 180…
Compass Pathways (CMPS) is a volatile, binary biotech with clear upside if regulatory momentum continues. With a market cap of ~$1.65B, roughly $3.03 in reported cash per share and bullish technicals, I recommend a mid-term long trade ahead of an upcoming FDA verdict. Entry, stop and target are provided with rationale and risk controls.
Nvidia's fundamentals and cash generation remain exceptional even after years of run-up. Q1-driven demand for AI infrastructure, rising memory prices, and a sizable capex commitment to Taiwan are shifting the narrative away from a structural slowdown. Valuation is rich but not irrational given $119B of free cash flow and industry positioning. This …
IREN has landed headline contracts with Microsoft, Nvidia and a $1.6B Dell procurement commitment, pushing its story from crypto miner to large-scale AI infrastructure provider. Those wins matter, but the company trades at an aggressive premium (market cap ~$21.4B; EV/EBITDA ~368.7) while burning cash (FCF -$1.105B) and carrying elevated leverage (…
JOYY traded off after a lukewarm quarter, but the stock now offers a rare combination of yield (6.6%), sub-0.5 book value and a PE of ~14.8. Momentum is turning positive and short interest has fallen from the peaks. This is a tactical long for traders willing to own through execution risk: entry $64.15, stop $58.00, target $80.00 over a mid-term 45…
<p>Nebius is converting rapid top-line growth into durable margins by vertically integrating data centers, power solutions and AI data services. That strategy amplifies customer stickiness and margin leverage, supporting a long trade sized for a tactical growth recovery.</p>
Coinbase is trading near $180 after a sharp run-down from last summer's highs. Revenue pressure and rate-driven risk have weighed on the stock, but the company still carries a healthy cash cushion, concrete cost savings from recent layoffs and a regulatory narrative that could re-accelerate product monetization. This trade idea lays out an actionab…
Texas Instruments (TXN) has ripped higher as investors rotate into semiconductor suppliers tied to AI. Fundamentals back a sustained analog rebound - ROE north of 30%, free cash flow of $3.72B, and reported 22% year-over-year analog sales growth - yet valuation is rich. This trade idea targets further re-rating if AI-driven system complexity contin…
Fluence Energy supplies industrial-scale battery systems and AI-enabled grid software to utilities and hyperscalers. With a $5.5B backlog, pre-qualification wins with major hyperscalers, and roughly 36 GWh of prospective data-center projects in development, the company sits at the intersection of renewables, long-duration storage, and the AI data-c…
Applied Optoelectronics (AAOI) is a high-volatility photonics play priced for perfection. The business sits at the intersection of data-center optics and AI infrastructure with strong order flow, but the stock carries rich multiples and execution risk. I’m taking a long position with defined risk — entry $179.00, stop $150.00, target $300.00 — and …
Uber is trading near $70 after a pullback that left fundamentals intact: market cap ~$143B, free cash flow ~$9.1B, P/E ~16.7 and ROE ~34.5%. Catalysts include a bold stake-and-offer for Delivery Hero, ongoing unit-economics improvements in Delivery, and continued margin leverage across Mobility and Freight. This trade idea takes a tactical long sta…
UP Fintech (TIGR) plunged after Chinese authorities named brokers for illegally soliciting cross-border business. With a class-action already forming and a material earnings event on 06/02/2026, we favor a tactical short over a mid-term (45 trading days) horizon. The trade is sized for volatility: entry at $5.00, stop at $6.00, target at $3.75.
Denali (DNLI) just crossed a major commercialization milestone with accelerated FDA approval of Avlayah for Hunter syndrome and retains full control of its progranulin replacement program (DNL593) after Takeda's exit. With a market cap near $3.08B, limited leverage and $3.52 of cash reported in recent ratios, the stock looks attractive for a tactic…
Savara (SVRA) is a clinical-stage company whose lead asset, MOLBREEVI, targets autoimmune pulmonary alveolar proteinosis (autoimmune PAP). With a Day 74 FDA letter indicating no advisory committee and a PDUFA date of 08/22/2026, the stock is trading as a binary approval bet. The balance sheet, short-interest profile, and recent regulatory progress …
FinVolution is showing tangible signs of international expansion and continues to return capital aggressively via buybacks and a higher dividend. At a $1.20B market cap, sub-4x PE and a sub-0.5x PB, the stock looks inexpensive relative to its recent strategic moves. This is a mid-term (45 trading days) trade idea to buy into improving fundamentals …
Adobe is trading near its 52-week low while still producing more than $10 billion in annual free cash flow. The balance sheet is solid, management has authorized a $25 billion buyback, and valuation metrics are attractive. This trade idea lays out a pragmatic long setup with defined risk management over a mid-term (45 trading days) horizon.
Texas Instruments is ripping higher as investors price in the companys expansion of 300mm wafer capacity and a renewed analog cycle driven by AI infrastructure. Balance-sheet strength, >20% analog sales growth commentary, and a tidy dividend make a tactical long worth considering with a disciplined stop and clearly defined horizon.
Natera (NTRA) is a market leader in genetic diagnostics with early traction in MRD and durable NIPT market share. Recent clinical readouts and analyst commentary point to accelerating MRD revenue and an expanding addressable market. Valuation is rich but not unreasonable for high-growth diagnostics; this trade targets upside toward analyst consensu…
Smithfield (SFD) combines strong cash flow, a 4%+ dividend and recent branded M&A, yet trades at ~10x earnings and an EV/EBITDA below 7. We think the market is overlooking branded upside and accretive M&A; buy SFD at $26.00 with a $30.00 target and $24.00 stop for a mid-term (45 trading days) swing.
Damora Therapeutics ($25.97) is a small, tightly staffed biotech with a clinical-stage mindset and a surprisingly clean balance sheet. For traders willing to stomach binary clinical outcomes, the stock offers a defined risk entry with clear upside to the prior 52-week high if a CALR-focused program shows early promise or the company announces partn…
KKR is a diversified alternative asset manager and insurance operator with a $85.3B market cap, a durable fee-bearing franchise and active capital recycling. At $95.00 the stock is trading well below prior highs and reflects short-term private-markets worries; we view the setup as a long-term trade with asymmetric upside driven by asset realization…
